ERBB2 and cancer: Felices et al. designed a TriKE of tri-specific biologic drugs containing distinct antibody fragments (including single-domain antibodies against CD16, single-chain antibodies against HER2 antigens on cancer cells, and IL-15), which could activate NK cells through different pathways [85].